Cingulate reports FY 2024 net loss $15.5M; cash runway extended to Q4 2025, NDA for CTx-1301 targeted mid-2025

Cingulate Inc.

Cash and equivalents $12.2M (vs $52k Dec 2023); working capital improved to $7.5M from -$9.6M.
Net loss narrowed to $15.5M from $23.5M in 2023; R&D expenses fell to $9.4M from $15.5M.
Pre-NDA FDA meeting scheduled April 2, 2025; NDA submission for CTx-1301 targeted mid-2025.
Phase 3 pediatric safety data showed no serious TEAEs across nine clinical trials.
Raised $17.5M in capital in 2024 via public offering, warrant inducement, and promissory note.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.